Neil Woodford just bought a dividend stock you’ve likely never heard of

A new stock Neil Woodford’s just bought and an old favourite look great value right now, says G A Chester.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

The big story from the FTSE 100 this week is the spectacular crash of sub-prime lender Provident Financial. With Neil Woodford owning 19% of the company — and publishing a defiant blog post on his investment — his recent buys and interesting views on other stocks have been rather cast into the shadows.

For example, he’s bought more shares in his top holding AstraZeneca and continued to build his stake in Lloyds for his Income Focus fund. The Black Horse is now his third-largest holding with a weighting of 3.9%.

However, I’m particularly interested in two other Woodford stocks that I happen to agree look great buys right now. One is a familiar blue-chip giant, whose shares he believes “have not looked as attractive as they are currently, for several years.” The other is a dividend stock you’ve probably never heard of that he’s just bought a 17% stake in.

Seriously undervalued

Woodford has held tobacco companies for decades but believes the “valuation opportunity” he identified all those years ago has now “largely played out.” With one exception. He continues to see Imperial Brands (LSE: IMB) — his last remaining holding in the sector — as seriously undervalued.

The company’s shares are currently trading at around 3,200p, which is a 22% discount to their all-time high of 4,130p achieved this time last year. As Woodford has pointed out, Imperial remains a highly cash generative business with a strong dividend-growth record. The decline in the shares has put it on an undemanding price-to-earnings (P/E) ratio of 11.8 with a smokin’ dividend yield of 5.4%.

Investor sentiment towards the industry hasn’t been helped by regulatory changes to address issues of addiction proposed last month by the US Food and Drug Administration. However, Woodford and his team argue that this could ultimately be beneficial to Imperial: “We see this as the beginning of a process to deregulate next-generation products.”

New buy

I spent yesterday evening reading the AIM admission document of Global Yachting Group — now GYG (LSE: GYG) — which listed on 5 July with a placing at 100p a share. I have to say, I like the cut of its jib.

This week’s update from Woodford’s Income Focus fund revealed: “We added a new stock to the portfolio when we participated in the initial public offering of GYG. It is a cash generative business, which is expected to pay an attractive dividend and support a progressive dividend policy going forward.”

Super-rich potential

GYG is a leading super-yacht painting, supply and maintenance company with a 17% share of the global market. Its experienced management team is looking to grow the business organically and has also identified a number of potential targets for strategic acquisitions that would complement the group’s existing offering.

The board intends to pay a current-year dividend yielding 3.2% on the IPO price. This is pro rata from the listing date based on an annualised yield of 6.4%. The shares are now trading at 117.5p (market cap £55m), so we’re looking at a yield of 2.7%, rising to 5.4%+ next year. The handsome dividend is supported by forecast earnings of 9p a share, rising to 11.2p, which gives an attractive P/E progression of 13.1 down to 10.5.

Finally, the balance sheet is decent, with the IPO having reduced net gearing of 93% at the last year-end to 38% on a pro forma basis.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

G A Chester has no position in any shares mentioned. The Motley Fool UK has recommended AstraZeneca, Imperial Brands, and Lloyds Banking Group. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes

More on Investing Articles

Concept of two young professional men looking at a screen in a technological data centre
Investing Articles

If I’d put £5,000 in Nvidia stock at the start of 2024, here’s what I’d have now

Nvidia stock was a massive winner in 2023 as the AI chipmaker’s profits surged across the year. How has it…

Read more »

Light bulb with growing tree.
Investing Articles

3 top investment trusts that ‘green’ up my Stocks and Shares ISA

I’ll be buying more of these investment trusts for my Stocks and Shares ISA given the sustainable and stable returns…

Read more »

Investing Articles

8.6% or 7.2%? Does the Legal & General or Aviva dividend look better?

The Aviva dividend tempts our writer. But so does the payout from Legal & General. Here he explains why he'd…

Read more »

a couple embrace in front of their new home
Investing Articles

Are Persimmon shares a bargain hiding in plain sight?

Persimmon shares have struggled in 2024, so far. But today's trading update suggests sentiment in the housing market's already improving.

Read more »

Market Movers

Here’s why the Unilever share price is soaring after Q1 earnings

Stephen Wright isn’t surprised to see the Unilever share price rising as the company’s Q1 results show it’s executing on…

Read more »

Investing Articles

Barclays’ share price jumps 5% on Q1 news. Will it soon be too late to buy?

The Barclays share price has been having a great time this year, as a solid Q1 gives it another boost.…

Read more »

Young black colleagues high-fiving each other at work
Investing Articles

The AstraZeneca share price lifts 5% on a top-and-bottom earnings beat

The AstraZeneca share price reached £120 today and helped push the FTSE 100 higher. Would I still buy this flying…

Read more »

Young black woman using a mobile phone in a transport facility
Market Movers

Meta stock slumps 13% after poor results. Here’s what I’ll do

Jon Smith flags up the reasons behind the fall in the Meta stock price overnight, along with his take on…

Read more »